Therapy and Outcome of Prolonged Veno-venous ECMO Therapy of Critically Ill ARDS Patients.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05338593

Enrollment

100

Registered

2022-04-21

Start date

2022-05-01

Completion date

2023-05-15

Last updated

2023-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extracorporeal Membrane Oxygenation Complication, Outcome, Fatal

Brief summary

In the context of the coronavirus (COVID-19) pandemic, healthcare systems worldwide faced an unprecedented shortage of severe ARDS. Critically affected patients were treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO) for complete respiratory failure early in the pandemic. Due to a shortage of resources in the sense of terminal equipment and adequately trained personnel with appropriate expertise in many countries and regions, a strict selection of suitable patients was made. Repeatedly, it was observed that patients under VV-ECMO also needed several weeks to recover sufficiently to generate device sufficient gas exchange. Due to the scarcity of VV-ECMO resources outside of the pandemic, the question arose whether a prolonged therapy still holds a sufficient prospect of success and what the course of treatment of such patients would be like.

Interventions

OTHEROutcome

Mortality rate of prolonged therapy.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

veno-venous extracorporeal membrane oxygenation

Exclusion criteria

veno-arterial extracorporeal membrane oxygenation

Design outcomes

Primary

Measure	Time frame	Description
Mortality	During intensive care treatment (Usually within 25 weeks)	Mortality rate under ongoing veno-venous extracorporeal membrane oxygenation over time

Secondary

Measure	Time frame	Description
Major bleeding	During intensive care treatment (Usually within 25 weeks)	Number of patients with critical bleeding events during therapy, needing red blood cell transfusion
critical device error	During intensive care treatment (Usually within 25 weeks)	Number of patients with a critical device errors of the veno-venous extracorporeal membrane oxygenation device.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026